How exactly do you know that Lympro has done nothing so far? They told us about the first collaboration, but that doesn't necessarily mean there aren't other deals already made or on the horizon. You've got to start somewhere. You saying it's worthless is no different than me saying it's worth billions. Neither of us have real evidence to back either of our claims. Wait for the next update, possibly after the next data presentation, before you draw the conclusion that Lympro is worthless.
Also, if you weren't expecting some lag time between deals being struck and revenue being generated from Lympro, then you were fooling yourself to begin with.
They have said all along that there is competition out there. The main goal was to be first to market, which they were. Lympro is not just Lympro anymore either. They are attempting to package the different diagnostics together to offer a suite of tests that will increase the accuracy and value of the whole package.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links